Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 5
1987 4
1988 1
1989 1
1990 5
1991 4
1992 1
1993 1
1994 5
1995 5
1996 7
1997 5
1998 2
1999 5
2000 4
2001 4
2002 5
2003 6
2004 4
2005 2
2006 6
2007 4
2008 2
2009 6
2010 1
2011 7
2012 5
2013 3
2014 4
2015 3
2016 5
2017 5
2018 3
2019 7
2020 5
2021 5
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Results by year

Filters applied: . Clear all
Page 1
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Pujade-Lauraine E, et al. Among authors: sorio r. J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17. J Clin Oncol. 2014. PMID: 24637997 Clinical Trial.
Idarubicin.
Crivellari D, Toffoli G, Lombardi D, Berretta M, Sorio R, Magri MD, Spazzapan S, Scuderi C, Veronesi A. Crivellari D, et al. Among authors: sorio r. Tumori. 2002 Jan-Feb;88(1 Suppl 1):S73-4. doi: 10.1177/030089160208800122. Tumori. 2002. PMID: 11989932 No abstract available.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Pignata S, et al. Among authors: sorio r. Lancet Oncol. 2014 Apr;15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28. Lancet Oncol. 2014. PMID: 24582486 Clinical Trial.
'Genetic profiling' and ovarian cancer therapy (review).
Vella N, Aiello M, Russo AE, Scalisi A, Spandidos DA, Toffoli G, Sorio R, Libra M, Stivala F. Vella N, et al. Among authors: sorio r. Mol Med Rep. 2011 Sep-Oct;4(5):771-7. doi: 10.3892/mmr.2011.512. Epub 2011 Jun 17. Mol Med Rep. 2011. PMID: 21687948 Review.
Ifosfamide in advanced/disseminated breast cancer.
Sorio R, Lombardi D, Spazzapan S, La Mura N, Tabaro G, Veronesi A. Sorio R, et al. Oncology. 2003;65 Suppl 2:55-8. doi: 10.1159/000073360. Oncology. 2003. PMID: 14586149 Review.
Can visual capture of sound separate auditory streams?
Valzolgher C, Giovanelli E, Sorio R, Rabini G, Pavani F. Valzolgher C, et al. Among authors: sorio r. Exp Brain Res. 2022 Mar;240(3):813-824. doi: 10.1007/s00221-021-06281-8. Epub 2022 Jan 20. Exp Brain Res. 2022. PMID: 35048159
144 results